

CERENIS THERAPEUTICS HOLDING

Limited company with share capital of € 915,413.15
Registered Office: 33-43 avenue Georges Pompidou – Bât. D
481 637 718 RCS TOULOUSE

**INFORMATION RELATED TO THE CANDIDACY OF RICHARD PASTERNAK TO SERVE AS DIRECTOR
PRESENTED TO THE COMBINED GENERAL MEETING OF JUNE 25, 2018**

SURNAME AND NAME: Richard PASTERNAK

AGE: 69

PROFESSIONAL REFERENCES AND ACTIVITIES IN OTHER COMPANIES OVER THE PAST FIVE YEARS:

Richard C. Pasternak has held the position of academic and biopharmaceutical clinical researcher for the past 35 years. He is currently Clinical Professor in the Department of Medicine and Pharmacology at Weill Cornell Medical College, New York. Dr. Pasternak has a long-standing interest in lipid disorders and atherosclerosis, in addition to patterns of practice and disease management, epidemiology and prevention. He was Vice President, Head of Cardiovascular Clinical Research and Head of Scientific Affairs and Scientific Leadership at Merck & Co from 2004 to 2010. He served as a key senior executive for Merck regarding critical issues related to worldwide scientific affairs, strategic business development issues, regulatory affairs and medical affairs. Prior to this, he was Director of Preventive Cardiology and Cardiac Rehabilitation at Massachusetts General Hospital from 1992 to 2004, and he was Associate Professor of Medicine at the Harvard Medical School.

Dr. Pasternak has authored more than 100 publications and has spoken widely on the development of drugs for the treatment and prevention of cardiovascular diseases, and about how academia and industry can better collaborate in biomedical research. He is currently a member of the Board of Directors of Magenta Medical Ltd.

POSITION HELD IN THE COMPANY:

Director (Chairman).

NUMBER OF THE COMPANY'S SHARES HELD

1,617